JAGUAR HEALTH, INC. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
JAGUAR HEALTH, INC. (JAGX) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 1.87% for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-20.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2018-04-09
- JAGUAR HEALTH, INC. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for the quarter ending 2017-03-31 was 1.95%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 3 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 6 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 9 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|---|
| 2017-09-30 | 1.87% 10-Q · filed 2017-11-20 | |||||
| 2017-06-30 | 1.87% 10-Q · filed 2017-08-09 | |||||
| 2017-03-31 | 1.95% 10-Q/A · filed 2017-06-23 | |||||
| 2016-12-31 | 2.00% 10-K · filed 2017-02-15 | 2.00% 10-Q · filed 2017-11-20 | ||||
| 2016-11-30 | 1.87% 10-K · filed 2017-02-15 | |||||
| 2016-11-29 | 1.87% 10-Q · filed 2017-11-20 | |||||
| 2016-11-08 | 1.45% 10-K · filed 2018-04-09 | |||||
| 2014-08-31 | 0.52% 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |